Hepatobiliary associations with inflammatory bowel disease.
Hepatobiliary disease is not uncommon in patients with inflammatory bowel disease (IBD). The most common autoimmune hepatic associations are primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH). The immunosuppressant medications used in the treatment of IBD also have potential hepatotoxicity. PSC is most commonly associated with IBD, specifically ulcerative colitis. AIH, a more classic autoimmune disease diagnosed commonly in isolation of other conditions in the same individual, is less commonly associated with IBD. Additionally, a subgroup of patients have features of both PSC and AIH, termed overlap syndrome, that is also sometimes seen in IBD patients. This review will discuss the most common liver disease associations seen in patients with IBD: PSC, AIH and overlap syndrome. Additionally, the most common drug-related hepatotoxicities encountered when treating IBD will be reviewed.
Knight
Crystal
C
Seattle Children's and University of Washington School of Medicine, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, 4800 Sand Point Way, NE, PO Box 5371/W-7830, Seattle, WA 98105, USA. crystal.knight@seattlechildrens.org
Murray
Karen F
KF
D015209:Cholangitis, Sclerosing / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D019693:Hepatitis, Autoimmune / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D015994:Incidence; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D013256:Steroids / Q000627:therapeutic use; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D013256:Steroids; D014580:Ursodeoxycholic Acid